Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
| Authors | |
|---|---|
| Year of publication | 2005 |
| Type | Article in Periodical |
| Magazine / Source | The hematology journal |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | multiple myeloma; hypertension; angiotensin-1-converting enzyme |
| Description | In a retrospective study we have sought to determine whether the administration of angiotensin-I-converting enzyme inhibitors (ACEI) influences the outcome of patients with multiple myeloma (MM). Patients with MM who underwent autologous peripheral blood stem cell transplantation (PBSCT) (n=168) were studied. Patients taking ACEI alone or in combination with other antihypertensive agents during the hospital admission for PBSCT were allocated to the ACEI group (n=25; 15%). In conclusion, according to our findings, ACEI administered during PBSCT have adverse effect on survival of patients with MM. |